Halfpenny Christopher, Benn Tracey, Scolding Neil
Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK.
Lancet Neurol. 2002 May;1(1):31-40. doi: 10.1016/s1474-4422(02)00004-2.
A decade ago, therapeutic strategies to remyelinate the CNS in diseases such as multiple sclerosis had much experimental appeal, but translation of laboratory success into clinical treatments appeared to be a long way off. Within the past 12 months, however, the first patients with multiple sclerosis have received intracerebral implants of autologous myelinating cells. Here we review the clinical and biological problems presented by multiple sclerosis disease processes, and the background to the development of myelin-repair strategies. We attempt to highlight those areas where difficulties have yet to be resolved, and draw on various experimental findings to speculate on how remyelinating therapies are likely to develop in the foreseeable future.
十年前，针对诸如多发性硬化症等疾病进行中枢神经系统髓鞘再生的治疗策略颇具实验吸引力，但将实验室成果转化为临床治疗似乎还有很长的路要走。然而，在过去的12个月里，首批多发性硬化症患者已经接受了自体髓鞘形成细胞的脑内植入。在此，我们回顾多发性硬化症疾病进程所呈现的临床和生物学问题，以及髓鞘修复策略发展的背景。我们试图突出那些尚未解决的难题领域，并借鉴各种实验结果来推测在可预见的未来髓鞘再生疗法可能如何发展。
